Loading
TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes clinical 0.65, literature 0.99, genetic association 0.59, somatic mutation 0.19, animal model 0.51).
In plain words · TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
No product in this corpus aims at TGFB2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TGFB2: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (myelodysplastic syndrome). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P61812; Human Protein Atlas TGFB2 tissue; Open Targets ENSG00000092969 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: de Martin et al, EMBO J, 1987, "Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family". Source.
Sources: HGNC HGNC:11768 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P61812 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000092969 (association with cancer (MONDO_0004992) 0.57; per-cancer scores at or above 0.5: myelodysplastic syndrome 0.57 (GraphQL API, CC0))
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2. Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 1q41 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Glioblastoma Multiforme 26 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TGFB2" OR ABSTRACT:"TGFB2" OR TITLE:"transforming growth factor beta 2" OR ABSTRACT:"transforming growth factor beta 2" OR TITLE:"Transforming growth factor beta-2 proprotein" OR ABSTRACT:"Transforming growth factor beta-2 proprotein") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGFB2, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.